New Therapeutic Option for Patients with metastatic castration-resistant Prostate Cancer Talazoparib in combination with Enzalutamide prolongs progression-free Survival

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：161 / 161
页数：1
相关论文
共 50 条
  • [1] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [2] Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (06) : 805 - 806
  • [3] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [4] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [5] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [6] Talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer: TALAPRO-2 trial
    Gupta, Prashant
    INDIAN JOURNAL OF UROLOGY, 2023, 39 (04) : 339 - 340
  • [7] Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer
    Mori, Keiichiro
    Kimura, Takahiro
    Onuma, Hajime
    Kimura, Shoji
    Yamamoto, Toshihiro
    Sasaki, Hiroshi
    Miki, Jun
    Miki, Kenta
    Egawa, Shin
    PROSTATE, 2017, 77 (10): : 1144 - 1150
  • [8] Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC)
    Vestris, Pierre-Gilles
    Gourtaud, Gilles
    Senechal, Cedric
    Sadreux, Yvanne
    Roux, Virginie
    Blanchet, Pascal
    Brureau, Laurent
    PROSTATE, 2022, 82 (02): : 269 - 275
  • [9] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [10] Development of enzalutamide for metastatic castration-resistant prostate cancer
    Bhattacharya, Suman
    Hirmand, Mohammad
    Phung, De
    van Os, Steve
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
12345